NCT07726433招募中2 期
A Multicenter, Exploratory Clinical Study of the Efficacy and Safety of Phentolamine and Palonosetron for the Prevention of Nausea and Vomiting Associated With Recom-Trastuzumab Therapy
Tianjin Medical University Cancer Institute and Hospital1 个研究点 分布在 1 个国家目标入组 56 人开始时间: 2026年6月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 56
- 试验地点
- 1
- 主要终点
- Overall Complete Response (CR) Rate
研究概览
简要总结
This study is a prospective, single-arm, multicenter, exploratory clinical trial divided into a screening phase, a treatment phase, and a follow-up phase. The study aims to evaluate the efficacy and safety of foslorapitant palonosetron for injection in preventing nausea and vomiting caused by treatment with recanituzumab. All patients who meet the inclusion criteria and do not meet any exclusion criteria are eligible for enrollment in this study and are scheduled to receive targeted therapy, antiemetic treatment, and follow-up.
Dosage Regimen Eligible subjects will receive a prophylactic antiemetic regimen consisting of foslorapitant and palonosetron.
The dosage regimen is as follows:
Day 1 (D1): Foslorapitant and palonosetron (218 mg foslorapitant and 0.25 mg palonosetron hydrochloride), administered intravenously (IV) 1 hour prior to chemotherapy.
Observe for two treatment cycles (C1-C2); Starting from the first dose, record the patient's daily vomiting frequency, severity of nausea, and medication adherence.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Sign a written informed consent form and voluntarily enroll in this study;
- •Be at least 18 years of age; gender is not a restriction;
- •Be a patient scheduled to receive treatment with Trastuzumab Rezetecan;
- •Have an ECOG performance status score of 0-2;
- •No ascites or pleural effusion requiring drainage;
- •No gastrointestinal obstruction, such as pyloric stenosis or intestinal obstruction;
- •Expected survival of ≥12 weeks;
- •Good organ and bone marrow function, defined as follows:
- •Hematologic System (No blood transfusions or treatment with hematopoietic growth factors within the past 14 days)
- •Absolute Neutrophil Count (ANC) ≥ 1.5×10⁹/L
- •Platelets (PLT) ≥ 100×10⁹/L
- •Hemoglobin (Hb) ≥ 90 g/L Liver Function
- •Total Bilirubin (TBIL) ≤ 1.5×ULN (For patients with Gilbert's syndrome: ≤ 3×ULN)
- •Alanine Aminotransferase (ALT) ≤ 2.5×ULN (Patients with liver metastases: ≤ 5×ULN)
- •Aspartate Aminotransferase (AST) ≤ 2.5×ULN (Patients with liver metastases: ≤ 5×ULN)
- •Albumin (ALB) ≥ 30 g/L Renal Function
- •Creatinine (Cr) ≤ 1.5×ULN
- •Creatinine Clearance (Ccr)
- •(Calculated only when creatinine > 1.5×ULN) Endogenous creatinine clearance ≥ 50 mL/min (Cockcroft-Gault formula) Cardiac Function
- •12-lead electrocardiogram No severe arrhythmias, and a mean Fridericia-corrected QT interval (QTc) of <450 ms (males) or <470 ms (females)
- •Echocardiogram Left ventricular ejection fraction (LVEF) ≥ 50%
- •Agree to cooperate in completing daily nausea and vomiting logs and scale assessments;
- •Understand the nature of this study; the patient and/or legal guardian voluntarily agree to participate in this trial and sign the informed consent form.
排除标准
- •Allergy to the study drug or its excipients;
- •Known contraindications to NK-1 receptor antagonists, 5-HT3 receptor antagonists, or dexamethasone;
- •Nausea or vomiting at the time of enrollment requiring treatment with antiemetics;
- •Use of medications with antiemetic effects within 2 days prior to the first dose;
- •Initiation of potent opioid analgesics within 48 hours prior to enrollment (adjustment of the dose of medications already in use is permitted);
- •Presence of conditions affecting the assessment of vomiting, such as gastrointestinal obstruction, gastroparesis, or intestinal obstruction;
- •Patients who are difficult to enroll due to clinically diagnosed psychiatric disorders;
- •Localized or active systemic infections requiring treatment;
- •Pregnant or breastfeeding women, as well as patients of childbearing age who refuse to use appropriate contraceptive measures during the course of this trial;
- •Patients who have participated in other clinical trials within 30 days prior to the first dose of the study drug (patients who failed screening for other clinical trials may be enrolled in this study);
- •Patients with other factors deemed by the investigator to be unsuitable for participation in this study, such as any physiological or psychological conditions that may increase study risks, affect patient adherence to the protocol, or interfere with the patient's ability to complete the trial.
结局指标
主要结局
Overall Complete Response (CR) Rate
时间窗: 0 to 120 hours after trastuzumab rezetecan infusion within Cycle 1 and Cycle 2 (each treatment cycle is 21 days)
The proportion of participants without any vomiting episodes and without receiving rescue antiemetic medication during the overall 0-120 hour period after trastuzumab rezetecan infusion.
次要结局
- Complete Protection (CP) Rate(0 to 168 hours after trastuzumab rezetecan infusion within Cycle 1 and Cycle 2 (each treatment cycle is 21 days))
- Complete Response (CR) Rate in Acute Phase (0-24 h)(0 to 24 hours after trastuzumab rezetecan infusion within Cycle 1 and Cycle 2 (each treatment cycle is 21 days))
- Complete Response (CR) Rate in Delayed Phase (24-120 h)(24 to 120 hours after trastuzumab rezetecan infusion within Cycle 1 and Cycle 2 (each treatment cycle is 21 days))
- Complete Response (CR) Rate in Very Delayed Phase (120-168 h)(120 to 168 hours after trastuzumab rezetecan infusion within Cycle 1 and Cycle 2 (each treatment cycle is 21 days))
- Complete Control (TC) Rate(0 to 168 hours after trastuzumab rezetecan infusion within Cycle 1 and Cycle 2 (each treatment cycle is 21 days))
- No Nausea Rate & No Vomiting Rate & No Rescue Medication Rate(0 to 168 hours after trastuzumab rezetecan infusion within Cycle 1 and Cycle 2 (each treatment cycle is 21 days))
- Rate of Trastuzumab Rezetecan Dose Delay or Reduction Due to Nausea and Vomiting(ntire duration of Cycle 1 and Cycle 2 (each treatment cycle is 21 days))
- Safety Endpoints (Adverse Events, Serious Adverse Events)(From informed consent signing to 30 days after last study drug administration)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
Multi-Cohort Study of Zeprumetostat Combinations for Relapsed/Refractory PTCLPTCL-NOSNCT07724782Tianjin Medical University Cancer Institute and Hospital33
尚未招募
不适用
The Efficacy of Combined Peripheral Blood CTCs and Serum HER2 Detection in Docetaxel-based Treatment for HER2 Low-expression Breast CancerPatients With Low HER2 Expression (IHC 1+ or IHC 2+/ISH-) and HER2 IHC 0 Advanced Breast CancerNCT07670182Tianjin Medical University Cancer Institute and Hospital100
招募中
不适用
A Multicenter observational study on the effectiveness and tolerability of Hexilak® Acne scar serum used with device-based procedures for acne scar treatment (Adjuvant Real-World Evidence Study).Acne ScarCTRI/2025/12/098453Menarini India Private Limited500
尚未招募
不适用
Efficacy of Lymphatic-Venous Anastomosis Plus Donepezil Versus Donepezil Alone for Alzheimer's DiseaseAlzheimer s DiseaseNCT07680660Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University216
尚未招募
不适用
A Prospective Multicenter Clinical Study on the Efficacy and Safety of the Zirconia Ceramic Hip Joint Prosthesis System After Its Market LaunchNCT07382050Peking University Third Hospital290